Genespire Secures €46.6 Million in Series B Financing
Genespire, an innovative biotechnology firm specializing in off-the-shelf gene therapies for children, has announced an impressive funding milestone. The company raised €46.6 million (around $52 million) in a Series B financing round, aimed at speeding up the development of its first pediatric in-vivo gene therapy. This marks one of the most significant private funding efforts for an Italian biotech company.
Details of the Financing
This funding round was co-led by well-known firms such as Sofinnova Partners, XGEN Venture, and CDP Venture Capital, along with Indaco SGR. The investment is dedicated to advancing GENE202, the leading therapeutic candidate aimed at treating Methylmalonic Acidemia (MMA), a rare genetic condition that disrupts the metabolism of amino acids and fats.
What is Methylmalonic Acidemia (MMA)?
MMA typically presents itself in infancy and can lead to serious health consequences, including high rates of mortality and morbidity. Common symptoms include muscle weakness, seizures, and developmental delays. Unfortunately, there are currently no effective treatments to modify the course of the disease. Genespire’s GENE202 aims to address this gap, using the company’s innovative Immune Shielded Lentiviral Vector (ISLV) platform, which enables the patient’s liver to produce a lifelong therapy through intravenous delivery.
Genespire's Unique Gene Therapy Approach
Genespire's approach marks a significant step forward in pediatric gene therapies, particularly for patients facing urgent medical needs. The ISLV technology, created by prominent gene therapy experts Professor Luigi Naldini and Dr. Alessio Cantore, is tailored for young patients and holds the promise of transforming the treatment of difficult genetic disorders.
Enhancing the Gene Therapy Pipeline
The financing will not only advance GENE202 to clinical trials but will also bolster Genespire's broader gene therapy initiatives, allowing for the exploration of additional therapies targeting various genetic conditions. This intensified focus on research and development reinforces the company’s dedication to innovation and delivering vital treatments to at-risk patient groups.
Leadership Views on the Funding
Karen Aiach-Pignet, CEO of Genespire, shared her excitement about the financing, saying, "Our groundbreaking ISLV platform enables us to introduce therapies that can significantly improve the lives of children facing genetic diseases. The strong support from our investors reflects their trust in our capabilities. We also want to thank our former CEO, Julia Berretta, whose efforts were crucial to this accomplishment. We look forward to our collaborations with our investors and partners as we work towards bringing GENE202 into clinical settings."
Lucia Faccio, a Partner at Sofinnova Partners, highlighted their commitment to Genespire, praising the remarkable skills of its team and their leading lentiviral technology, with a shared goal of advancing single-treatment solutions for pediatric genetic disorders.
Paolo Fundarò from XGEN Venture remarked that recent advancements in gene therapy underscore the promising future of Genespire's methods, suggesting exciting opportunities are on the horizon.
Additional Context on CDP Venture Capital
Agostino Scornajenchi, General Manager of CDP Venture Capital, pointed out the strategic significance of investing in biotech as part of Italy's broader economic development strategy and highlighted Genespire's role in setting new benchmarks in gene therapy.
With the conclusion of this financing round, Marco Dieci from CDP Venture Capital will join Genespire’s Board of Directors, further strengthening the company’s strategic guidance as it progresses.
About Genespire
Founded in 2020 in Milan by Prof. Luigi Naldini and Dr. Alessio Cantore, Genespire is focused on creating innovative gene therapies specially designed for children with genetic disorders. The company employs ISLV technology to enable these patients to produce therapeutic agents throughout their lives, potentially offering curative options for inherited metabolic diseases that currently have a significant unmet medical need.
Frequently Asked Questions
What is the primary aim of Genespire's latest financing?
The recent funding of €46.6 million is primarily intended to advance Genespire’s pediatric gene therapy, GENE202, which is designed to treat Methylmalonic Acidemia.
Who are the key investors in this Series B financing?
The investment round was co-led by Sofinnova Partners, XGEN Venture, and CDP Venture Capital, in partnership with Indaco SGR.
Can you explain Methylmalonic Acidemia (MMA)?
Methylmalonic Acidemia (MMA) is a genetic disorder that disrupts metabolism and can result in serious health issues, such as seizures and developmental delays.
What technology does Genespire utilize in its therapies?
Genespire employs Immune Shielded Lentiviral Vector (ISLV) technology, allowing patients' livers to produce long-term therapeutic agents.
In what other ways will the funds be utilized beyond GENE202's development?
The financing will also support the discovery and preclinical development of additional gene therapy solutions for various genetic disorders.
